Paul Swiecicki

Paul Swiecicki

Auto-generated profile, based on publicly available information

Paul Swiecicki

University of Michigan Rogel Cancer Center, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JGJessica L. Geiger
Jessica L. Geiger
NINofisat Ismaila
Nofisat Ismaila
BBBeth Beadle
Beth Beadle
JCJimmy J. Caudell
Jimmy J. Caudell
NCNicole Chau
Nicole Chau
Patrick HaPatrick Ha
Patrick Ha
PURPOSE: To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy.METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, neuroradiology, pathology, and patient advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2020. Outcomes of interest included survival, diagnostic accuracy, disease recurrence, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTS: The literature search identified 293 relevant studies to inform the evidence base for this guideline. Six main clinical questions were addressed, which included subquestions on preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, and follow-up evaluations.RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address the diagnosis and appropriate preoperative evaluations for patients with a salivary gland malignancy, therapeutic procedures, and appropriate treatment options in various salivary gland histologies. Additional information is available at www.asco.org/head-neck-cancer-guidelines .

26 October 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YCYue Cao
Yue Cao
CHCatherine T. Haring
Catherine T. Haring
CBCollin Brummel
Collin Brummel
CBChandan Bhambhani
Chandan Bhambhani
MAMadhava Aryal
Madhava Aryal
JBJ. Chad Brenner
J. Chad Brenner
Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with tumor progression after chemoradiation, and (ii) to compare the predictive value of ctDNA to imaging biomarkers of MRI and FDG-PET.Experimental Design: Serial blood samples were collected from patients with AJCC8 stage III OPSCC (n = 34) enrolled on a randomized trial: pretreatment; during chemoradiation at weeks 2, 4, and 7; and posttreatment. All patients also had dynamic-contrast-enhanced and diffusion-weighted MRI, as well as FDG-PET scans pre-chemoradiation and week 2 during chemoradiation. ctDNA values were analyzed for prediction of freedom from progression (FFP), and correlations with aggressive tumor subvolumes with low blood volume (TVLBV) and low apparent diffusion coefficient (TVLADC), and metabolic tumor volume (MTV) using Cox proportional hazards model and Spearman rank correlation.Results: Low pretreatment ctDNA and an early increase in ctDNA at week 2 compared with baseline were significantly associated with superior FFP (P < 0.02 and P < 0.05, respectively). At week 4 or 7, neither ctDNA counts nor clearance were significantly predictive of progression (P = 0.8). Pretreatment ctDNA values were significantly correlated with nodal TVLBV, TVLADC, and MTV pre-chemoradiation (P < 0.03), while the ctDNA values at week 2 were correlated with these imaging metrics in primary tumor. Multivariate analysis showed that ctDNA and the imaging metrics performed comparably to predict FFP.Conclusions: Early ctDNA kinetics during definitive chemoradiation may predict therapy response in stage III OPSCC.

10 May 2023 in Cancer
Verified
Journal Article
Open access
CHCatherine T. Haring
Catherine T. Haring
LKLulia A. Kana
Lulia A. Kana
SDSarah Marie Dermody
Sarah Marie Dermody
CBCollin Brummel
Collin Brummel
JMJonathan B. McHugh
Jonathan B. McHugh
PSPaul L. Swiecicki
Paul L. Swiecicki
Background: Development of evidence‐based post‐treatment surveillance guidelines in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is limited by comprehensive documentation of patterns of recurrence and metastatic spread.Methods: A retrospective analysis of patients diagnosed with R/M HNSCC at a National Cancer Institute‐designated cancer center between 1998– 2019 was performed (n = 447). Univariate and multivariate analysis identified patterns of recurrence and predictors of survival.Results: Median overall survival (mOS) improved over time (6.7 months in 1998–2007 to 11.8 months in 2008–2019, p = .006). Predictors of worse mOS included human papillomavirus (HPV) negativity (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.2–2.6), high neutrophil/lymphocyte ratio (HR, 2.1 [1.4–3.0], disease‐free interval (DFI) ≤6 months (HR, 1.4 [1.02–2.0]), and poor performance status (Eastern Cooperative Oncology Group, ≥2; HR, 1.91.1–3.4). In this cohort, 50.6% of recurrences occurred within 6 months of treatment completion, 72.5% occurred within 1 year, and 88.6% occurred within 2 years. Metachronous distant metastases were more likely to occur in patients with HPV‐positive disease (odds ratio [OR], 2.3 [1.4–4.0]), DFI >6 months (OR, 2.4 [1.5–4.0]), and body mass index ≥30 (OR, 2.3 [1.1–4.8]). Oligometastatic disease treated with local ablative therapy was associated with improved survival over polymetastatic disease (HR, 0.36; 95% CI, 0.24–0.55).Conclusion: These data regarding patterns of distant metastasis in HNSCC support the clinical utility of early detection of recurrence. Patterns of recurrence in this population can be used to inform individualized surveillance programs as well as to risk‐stratify eligible patients for clinical trials.Plain Language Summary: After treatment for head and neck cancer (HNC), patients are at risk of recurrence at prior sites of disease or at distant sites in the body. This study includes a large group of patients with recurrent or metastatic HNC and examines factors associated with survival outcomes and recurrence patterns. Patients with human papillomavirus (HPV)‐positive HNC have good survival outcomes, but if they recur, this may be in distant regions of the body and may occur later than HPV‐negative patients. These data argue for personalized follow‐up schedules for patients with HNC, perhaps incorporating imaging studies or novel blood tests.

1 February 2020 in Oral Oncology
Verified
Journal Article
Closed access
WBWhitney H. Beeler
Whitney H. Beeler
EBEmily L. Bellile
Emily L. Bellile
KCKeith A. Casper
Keith A. Casper
EJElizabeth Jaworski
Elizabeth Jaworski
NBNicholas J. Burger
Nicholas J. Burger
PSPaul L. Swiecicki
Paul L. Swiecicki

22 June 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
CHCatherine T. Haring
Catherine T. Haring
CBChandan Bhambhani
Chandan Bhambhani
CBCollin Brummel
Collin Brummel
BJBrittany Jewell
Brittany Jewell
EBEmily Bellile
Emily Bellile
JBJ. Chad Brenner
J. Chad Brenner
Https://doi.org/10.18632/oncotarget.27992 Catherine T. Haring, Chandan Bhambhani, Collin Brummel, Brittany Jewell, Emily Bellile, Molly E. Heft Neal, Erin Sandford, Ryan M. Spengler, Apurva Bhangale,...

31 May 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
AKAlon Kahana
Alon Kahana
SUShelby P. Unsworth
Shelby P. Unsworth
CAChristopher A. Andrews
Christopher A. Andrews
MCMay P. Chan
May P. Chan
SBScott C Bresler
Scott C Bresler
FWFrancis P. Worden
Francis P. Worden
Background: Basal cell carcinoma (BCC) is a common skin cancer often curable by excision; however, for patients with BCC around the eye, excision places visual organs and function at risk. In this article, we test the hypothesis that use of the hedgehog inhibitor vismodegib will improve vision-related outcomes in patients with orbital and extensive periocular BCC (opBCC). Materials and Methods: In this open-label, nonrandomized phase IV trial, we enrolled patients with globe- and lacrimal drainage system–threatening opBCC. To assess visual function in the context of invasive periorbital and lacrimal disease, we used a novel Visual Assessment Weighted Score (VAWS) in addition to standard ophthalmic exams. Primary endpoint was VAWS with a score of 21/50 (or greater) considered successful, signifying globe preservation. Tumor response was evaluated using RECIST v1.1. Surgical specimens were examined histologically by dermatopathologists. Results: In 34 patients with opBCC, mean VAWS was 44/50 at baseline, 46/50 at 3 months, and 47/50 at 12 months or postsurgery. In total, 100% of patients maintained successful VAWS outcome at study endpoint. Compared with baseline, 3% (95% confidence interval [CI], 0.1–15.3) experienced major score decline (5+ points), 14.7% (95% CI, 5 to 31.1) experienced a minor decline (2–4 points), and 79.4% experienced a stable or improved score (95% CI, 62.1–91.3). A total of 56% (19) of patients demonstrated complete tumor regression by physical examination, and 47% (16) had complete regression by MRI/CT. A total of 79.4% (27) of patients underwent surgery, of which 67% (18) had no histologic evidence of disease, 22% (6) had residual disease with clear margins, and 11% (3) had residual disease extending to margins. Conclusion: Vismodegib treatment, primary or neoadjuvant, preserves globe and visual function in patients with opBCC. Clinical trail identification number.NCT02436408. Implications for Practice: Use of the antihedgehog inhibitor vismodegib resulted in preservation of end-organ function, specifically with regard to preservation of the eye and lacrimal apparatus when treating extensive periocular basal cell carcinoma. Vismodegib as a neoadjuvant also maximized clinical benefit while minimizing toxic side effects. This is the first prospective clinical trial to demonstrate efficacy of neoadjuvant antihedgehog therapy for locally advanced periocular basal cell carcinoma, and the first such trial to demonstrate end-organ preservation.